Patients With Acute on Chronic Liver Failure Grade 3 Have Greater 14-Day Waitlist Mortality Than Status-1a Patients.
Journal
Hepatology (Baltimore, Md.)
ISSN: 1527-3350
Titre abrégé: Hepatology
Pays: United States
ID NLM: 8302946
Informations de publication
Date de publication:
07 2019
07 2019
Historique:
received:
14
01
2019
accepted:
11
03
2019
pubmed:
26
3
2019
medline:
23
6
2020
entrez:
26
3
2019
Statut:
ppublish
Résumé
Patients listed for liver transplantation (LT) as status 1a currently receive the highest priority on the waiting list. The presence of acute on chronic liver failure (ACLF) with three or more organs failing (ACLF-3) portends low survival without transplantation, which may not be reflected by the Model for End-Stage Liver Disease-Sodium (MELD-Na) score. We compared short-term waitlist mortality for patients listed status 1a and those with ACLF-3 at listing. Data were analyzed from the United Network for Organ Sharing database, years 2002-2014, for 3,377 patients listed status 1a and 5,099 patients with ACLF-3. Candidates with ACLF were identified based on the European Association for the Study of the Liver Chronic Liver Failure Consortium criteria. MELD-Na score was treated as a categorical variable of scores <36, 36-40, and >40. We used competing risks regression to assess waitlist mortality risk. Evaluation of outcomes through 21 days after listing demonstrated a rising trend in mortality among ACLF-3 patients at 7 days (18.0%), 14 days (27.7%), and 21 days (32.7%) (P < 0.001) compared to a stable trend in mortality among individuals listed as status 1a at 7 days (17.9%), 14 days (19.3%), and 21 days (19.8%) (P = 0.709). Multivariable modeling with adjustment for MELD-Na category revealed that patients with ACLF-3 had significantly greater mortality (subhazard ratio, 1.45; 95% confidence interval, 1.31-1.61) within 14 days of listing compared to status-1a candidates. Analysis of the interaction between MELD-Na category and ACLF-3 showed that patients with ACLF-3 had greater risk of 14-day mortality than status-1a-listed patients, across all three MELD-Na categories. Conclusion: Patients with ACLF-3 at the time of listing have greater 14-day mortality than those listed as status 1a, independent of MELD-Na score; these findings illustrate the importance of early transplant evaluation and consideration of transplant priority for patients with ACLF-3.
Identifiants
pubmed: 30908660
doi: 10.1002/hep.30624
pmc: PMC6597310
mid: NIHMS1034144
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
334-345Subventions
Organisme : NIDDK NIH HHS
ID : T32 DK007740
Pays : United States
Informations de copyright
© 2019 by the American Association for the Study of Liver Diseases.
Références
Ann Intern Med. 2002 Dec 17;137(12):947-54
pubmed: 12484709
Ann Surg. 2003 May;237(5):666-75; discussion 675-6
pubmed: 12724633
Transplantation. 2006 Jan 27;81(2):195-201
pubmed: 16436962
BMJ. 2007 Oct 20;335(7624):806-8
pubmed: 17947786
Am J Transplant. 2010 Dec;10(12):2658-64
pubmed: 21087414
Gastroenterol Clin North Am. 2011 Sep;40(3):523-39
pubmed: 21893272
Hepatology. 2012 Jan;55(1):192-8
pubmed: 21898487
Hepatology. 2012 Mar;55(3):965-7
pubmed: 22213561
Gastroenterology. 2013 Jun;144(7):1426-37, 1437.e1-9
pubmed: 23474284
Transplantation. 2013 Jul 27;96(2):211-6
pubmed: 23765112
J Hepatol. 2014 Nov;61(5):1038-47
pubmed: 24950482
Gastroenterology. 2015 Mar;148(3):547-55
pubmed: 25461851
Hepatology. 2015 Jul;62(1):232-42
pubmed: 25800029
J Hepatol. 2015 Apr;62(1 Suppl):S131-43
pubmed: 25920082
Ann Intern Med. 2016 Jun 7;164(11):724-32
pubmed: 27043883
Hepatol Int. 2016 Sep;10(5):838-46
pubmed: 27221700
Nat Rev Dis Primers. 2016 Jun 09;2:16041
pubmed: 27277335
J Immunol. 2016 Nov 15;197(10):3755-3761
pubmed: 27815438
PLoS One. 2017 Dec 5;12(12):e0188151
pubmed: 29206839
J Clin Gastroenterol. 2018 Nov/Dec;52(10):913-917
pubmed: 29356783
Aliment Pharmacol Ther. 2018 Jun;47(11):1502-1510
pubmed: 29611203
J Hepatol. 2018 Sep;69(3):617-625
pubmed: 29709681
Hepatology. 2018 Dec;68(6):2325-2337
pubmed: 29790188
Liver Transpl. 2019 Mar;25(3):459-468
pubmed: 30536705
Gastroenterology. 2019 Apr;156(5):1381-1391.e3
pubmed: 30576643
Hepatology. 2019 May;69(5):2150-2163
pubmed: 30615211
Stat Med. 1985 Jan-Mar;4(1):87-90
pubmed: 3992076